TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Stock Information for Kintara Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.